The downfall of TBA-354 - a possible explanation for its neurotoxicity via mass spectrometric imaging.

Ntshangase S, Shobo A, Kruger HG, Asperger A, Niemeyer D, Arvidsson PI, Govender T, Baijnath S

Xenobiotica 48 (9) 938-944 [2018-09-00; online 2017-10-13]

1. TBA-354 was a promising antitubercular compound with activity against both replicating and static Mycobacterium tuberculosis (M.tb), making it the focal point of many clinical trials conducted by the TB Alliance. However, findings from these trials have shown that TBA-354 results in mild signs of reversible neurotoxicity; this left the TB Alliance with no other choice but to stop the research. 2. In this study, mass spectrometric methods were used to evaluate the pharmacokinetics and spatial distribution of TBA-354 in the brain using a validated liquid chromatography tandem-mass spectrometry (LCMS/MS) and mass spectrometric imaging (MSI), respectively. Healthy female Sprague-Dawley rats received intraperitoneal (i.p.) doses of TBA-354 (20 mg/kg bw). 3. The concentrationtime profiles showed a gradual absorption and tissue penetration of TBA-354 reaching the C max at 6 h post dose, followed by a rapid elimination. MSI analysis showed a time-dependent drug distribution, with highest drug concentration mainly in the neocortical regions of the brain. 4. The distribution of TBA-354 provides a possible explanation for the motor dysfunction observed in clinical trials. These results prove the importance of MSI as a potential tool in preclinical evaluations of suspected neurotoxic compounds.

Drug Discovery and Development (DDD) [Collaborative]

PubMed 28859520

DOI 10.1080/00498254.2017.1375168

Crossref 10.1080/00498254.2017.1375168

Publications 7.1.2